InVera Medical's New Vein Device Wins European Approval, Targeting a Silent Epidemic

GALWAY, Ireland – February 13, 2026 – Millions of Europeans suffering from the pain and discomfort of diseased leg veins may soon have a new, less invasive treatment option. Irish medical technology company InVera Medical announced today it has received European regulatory approval, known as a CE Mark, for its InVera Infusion Device, a novel system designed to transform the treatment of varicose veins and other forms of Chronic Venous Disease (CVD).

The approval allows the Galway-based firm to market its device across the European Union, entering a competitive field with an innovative approach that could significantly alter the patient experience and expand access to care.

The Overlooked Burden of Venous Disease

Chronic Venous Disease is one of modern healthcare's most prevalent yet undertreated conditions. Affecting an estimated one in four adults, it encompasses a range of issues from visible spider and varicose veins to more severe complications like chronic swelling, skin changes, and painful leg ulcers. Despite impacting over 120 million people across Europe and the United States, a staggering gap in care persists. Current estimates suggest that only about 1% of individuals living with the disease receive any form of interventional treatment each year.

This treatment gap is fueled by several factors, including a lack of awareness and the perceived invasiveness of existing procedures. For many, the condition progresses untreated, leading to a diminished quality of life and a significant burden on healthcare systems, which can consume up to 2% of national health budgets in Western countries for CVD management.

InVera Medical aims to directly address this gap by making treatment more accessible and less daunting for both patients and physicians.

A New Era Beyond Thermal Ablation

For years, the standard for minimally invasive vein treatment has been thermal ablation, using either laser or radiofrequency energy to heat and seal the diseased vein from the inside. While effective, these procedures typically require tumescent anesthesia—multiple injections of a dilute local anesthetic along the entire length of the vein to protect surrounding tissue from the heat. This can be uncomfortable for the patient and carries a small risk of nerve or skin injury.

InVera’s device joins a new wave of non-thermal technologies designed to circumvent these issues. The InVera Infusion Device utilizes a thin, flexible catheter, inserted into the vein under ultrasound guidance, a technique familiar to vascular specialists. It is designed to enhance the delivery of physician-specified agents to treat the vein without using any heat.

This non-thermal approach offers several key advantages. The procedure can be performed in a standard doctor's office, requires only a single injection of local anesthetic at the catheter entry site, and eliminates the need for specialized, capital-intensive hospital equipment. This not only improves patient comfort and reduces recovery time but also lowers the logistical and financial barriers to providing care.

"Securing CE Mark is a major milestone for InVera Medical and a significant step towards making this technology available to patients across Europe," said Stephen Cox, CEO and Co-Founder of InVera Medical, in a statement. "Our focus has been on developing a less-invasive, effective non-thermal approach that fits easily into existing clinical practice while improving the treatment experience for both physicians and patients."

An Irish Startup in a Field of Giants

Founded in 2018, InVera Medical is stepping into a market projected to reach over $2.5 billion in Europe by 2030. The company will compete with established medical device giants like Medtronic, which markets the VenaSeal glue-based system, and Boston Scientific, a leader in radiofrequency ablation.

The key to disrupting this market lies in differentiation. While other non-thermal options exist, such as medical adhesives (cyanoacrylate) or mechanochemical ablation, InVera is betting on the unique advantages of its infusion-based system. By focusing on a single-injection, office-based procedure, the company is positioning itself at the forefront of the patient-centric trend in vascular care.

The backing of life science venture capital firms like Fountain Healthcare Partners suggests strong investor confidence in the company's technology and strategy. Achieving the rigorous CE Mark under the EU's updated Medical Device Regulation (MDR) further validates the device's safety and performance profile, giving it a solid foundation for its European launch.

The Path from Approval to Widespread Adoption

While the CE Mark is a critical victory, it marks the beginning of a new chapter for InVera Medical, not the end. The next major hurdle is securing reimbursement from national health systems across the continent. The reimbursement landscape in Europe is fragmented, with each country—from Germany's G-BA to the UK's NICE—having its own process for evaluating the clinical and economic value of new technologies.

InVera's success will depend on its ability to present robust clinical data demonstrating that its device is not only safe and effective but also cost-effective compared to existing treatments. The company's value proposition—reducing the need for hospital resources, specialized equipment, and extensive anesthesia—will be a central part of its argument to payers.

If successful, the InVera Infusion Device could play a pivotal role in shifting the paradigm of venous disease care, moving it firmly into the outpatient clinic and making effective intervention a reality for a much larger portion of the millions who suffer in silence.